MANF Neurotrophic Factor Sequence Correction for Parkinson's
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Parkinson's disease and other neurodegenerative disorders lack effective neuroprotective agents to prevent dopaminergic neuron degeneration, with existing growth factors showing variable efficacy and potential amino acid sequence errors in previous studies on MANF.
Innovation Solution
Characterization of the mesencephalic-astrocyte-derived neurotrophic factor (MANF) and its genetic sequence, along with recombinant production methods, to develop therapeutic and diagnostic tools for MANF-dependent conditions, including pharmaceutical compositions and gene therapy applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If GDNF is used to protect dopaminergic neurons in Parkinson's disease, then neuronal survival is improved, but clinical efficacy remains controversial and variable
Solution Approach 1:
The patent creates a corrected copy of the MANF protein sequence (correcting the amino acid substitution at position 176 from proline to arginine) to ensure accurate replication of the native protein's neuroprotective function, thereby improving reliability while reducing variability in clinical response
Solution Approach 2:
The patent modifies the amino acid sequence parameter at position 176 (changing from proline to arginine) to correct the sequence error identified in previous studies, ensuring the MANF protein maintains its intended neuroprotective properties and reduces clinical variability
2Productivity
If MANF polypeptide with amino acid substitution at position 176 is used in previous studies, then experimental results were obtained, but the results are not relevant to the true MANF function due to sequence error
Solution Approach 1:
The patent provides the correct amino acid sequence of MANF (with arginine at position 176) as an accurate reference copy, enabling future research to produce relevant and meaningful results by using the true native sequence rather than the erroneous substituted version
Solution Approach 2:
The patent corrects the amino acid sequence parameter at position 176 from proline to arginine, thereby improving measurement precision and ensuring that subsequent research using this corrected sequence will yield accurate and relevant findings about MANF's true neuroprotective function
3Adaptability or versatility
If new neurotrophic factors are identified and characterized, then therapeutic options for neurodegenerative disorders are expanded, but development time and resource investment increase
Solution Approach 1:
The patent performs preliminary characterization of the MANF protein sequence, expression patterns, and neuroprotective function in advance, establishing a solid foundation that accelerates future therapeutic development by eliminating the need for repetitive basic research on MANF's fundamental properties
Solution Approach 2:
The patent provides complete nucleic acid and amino acid sequences of MANF as reusable reference copies, enabling other researchers to quickly replicate and build upon these findings without having to perform time-consuming sequence determination and characterization from scratch
Data Source
Figure 1A~1E
Figure 2A~2H
Figure 3A~3O
AI summary
The present invention generally relates to the field of treatment of neuronal disorders and more particularly to neurotrophic factor MANF and uses thereof. The present invention provides a pharmaceutical compound comprising MANF nucleic acid molecule, MANF protein or a functional fragment thereof for the treatment of a peripherial neuropathy including Alzheimer's disease, Parkinson's disease, epilepsy, drug addiction and ischemic brain injury.